allergic rhinitis
Conditions
Interventions
personalized probiotic adjuvant therapy group:Personalized probiotic products
group of probiotic products without individual screening:Unpaired probiotic products
placebo group:placebo
Sponsors
Wuxi Children's Hospital
Eligibility
Sex/Gender
All
Age
3 Years to 12 Years
Inclusion criteria
Inclusion criteria: 1. 3-12 years old. 2. Clinically diagnosed as IgE-mediated type I allergy patients. 3. The patient must have been diagnosed with rhinitis for at least 6 months, and the patient's immunoglobulin E value is greater than 120 IU/mL, and the eosinophilic white blood cell value is greater than 0.6 × 103/uL. 4. Can cooperate with the collection of experimental specimens and regular return visits. 5. The patient or family members have signed the subject's consent form. 6. All rhinitis and allergy-related drugs can be stopped one month before the trial (the nasal wash can be reserved).
Exclusion criteria
Exclusion criteria: 1. Congenital intestinal abnormalities, such as Hirschsprungs disease or intestinal atresia, were assessed by physicians as not suitable for inclusion in this clinical trial. 2. Other gastrointestinal diseases with symptoms of intestinal inflammation and increased permeability. 3. Those who have taken immunosuppressive drugs, steroids, various antibiotics, and T cell inhibitor ointments within 4 weeks. 4. Non-rhinitis. 5. Clinically diagnosed patients with asthma. 6. The patient has been consuming probiotic-related products (bacteria powder,yogurt or other fermented foods) continuously (for five or more days in a row) in the past month. 7. Those who have participated in other clinical trials and are taking experimental drugs in the past 1 month, use nasal sprays for five or more days a week, use systemic steroids, testosterone, or high-dose anti-inflammatory drugs (such as greater than 600 mg/day of aspirin). 8. During the test period of more than 10 days, no probiotics were taken. 9. Patients who have plans to change their rhinitis medication in the short term. 10. Others who have been evaluated by a physician as unsuitable for entry into the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| height;weight;fecal microbiota;blood routine; | — |
Countries
China
Contacts
Public ContactWenwei Lu
Outcome results
None listed